Clinico-pathological features predicting indication to mastectomy in breast cancer patients achieving complete response after neoadjuvant therapy: A retrospective analysis of the EUSOMA database
- PMID: 40009908
- DOI: 10.1016/j.ejso.2025.109643
Clinico-pathological features predicting indication to mastectomy in breast cancer patients achieving complete response after neoadjuvant therapy: A retrospective analysis of the EUSOMA database
Abstract
Aims: We investigated factors related to the type of surgery, i.e. mastectomy versus breast conserving surgery (BCS), in breast cancer (BC) patients with complete pathologic response in the breast (ypT0) after neoadjuvant therapy (NAT).
Methods: A retrospective analysis from the EUSOMA database was performed using data from 55 certified centers across 14 European countries, including ypT0 BC patients (i.e., neither invasive nor in situ residuals), treated between 2017 and 2022. Variables analyzed included year of surgery, age, number and distribution of tumor focality, extent, clinical and pathological stages, and biologic subtype. Logistic regression was used to identify predictors of surgical choice. The Kaplan-Meier method was used for comparison of local recurrence-free survival (LRFS) between surgical groups.
Results: Of 1416 BC patients included, 67.5 % underwent BCS and 32.5 % mastectomy. At multivariable analysis, factors increasing the likelihood of mastectomy included: more recent year of surgery [odds ratio (OR) 2.61, 95 % confidence interval (95%CI): 1.51-4.51,p = 0.001], younger age (OR: 0.96, 95%CI: 0.95-0.97,p < 0.001), multifocality (OR: 2.20, 95%CI: 1.61-3.00,p < 0.001) and multicentricity (OR: 12.66, 95%CI: 6.82-23.49,p < 0.001), advanced clinical tumor stage (OR: 14.54, 95%CI: 5.80-36.47,p < 0.001), and baseline axillary nodal involvement (OR: 1.56, 95%CI: 1.12-2.17,p = 0.009). Comparison between groups did not show a significant difference in LRFS (p = 0.389).
Conclusion: Many BC patients undergo mastectomy despite achieving complete response of primary tumor after NAT. Patients-related and tumor-related features, as well as having surgery in more recent years, seems to influence this choice. Our findings suggest the need for an optimized decision-making to spare unnecessary mastectomies.
Keywords: Breast cancer; Breast conserving surgery; Mastectomy; Neoadjuvant therapy; Pathological complete response.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:FM: Grant for presentations: Lilly, Gilead, Pfizer, Travel grant: Lilly, Gilead, Pfizer.KFL: Unrelated advisory funding from PfizerLF: Advisory Board AstraZenecaAK: Advisory Board/Consultation: Akira Medical Sciences, Resitu AB; Honoraria: Kubtec, Pfizer, Astra Zeneca, Endomag (all to the institute of the author); Travel Expenses: Elsevier, GBCC, UEMS, ESSO, Endomag. All outside the scope of the present work.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical